Spinal cord injury therapy maker InVivo Therapeutics registers with the SEC for a $10 million funding round.
Spinal injury therapy maker InVivo Therapeutics Holdings Corp. (OTC:NVIV) is preparing a $10 million offering, SEC filings show.
Details haven't yet been made public regarding pricing, but the company expects to use the proceeds for research & development, working capital, capital expenditures and other general corporate purposes.
InVivo, co-founded in 2005 by industry celebrity Robert Langer, took itself public with a reverse merger last year.
The company filed its first investigational device exemption in July 2011 for a biopolymer scaffolding device intended to treat acute spinal cord injuries. InVivo anticipates approval for its IDE in 2012, at which point it can begin human clinical studies.
InVivo is a pre-revenue company, with losses totalling $12.7 million since inception, according to SEC filings.
The company has managed to pare losses and deficits in the last year, although its assets have diminished as well.
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
If you read nothing else today, make sure you're still in the know with MassDevice +3.